Premium
Antipyrine metabolism in acute hepatic porphyria in relapse and remission.
Author(s) -
Birnie GG,
McColl KE,
Thompson GG,
Moore MR,
Goldberg A,
Brodie MJ
Publication year - 1987
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1987.tb03059.x
Subject(s) - porphobilinogen , medicine , porphyria , acute intermittent porphyria , endocrinology , metabolism , urine , excretion , urinary system , gastroenterology , oral administration , chemistry
Antipyrine kinetics following a single oral dose were obtained in porphyric patients in attack and in remission and in controls. The clearance of antipyrine was significantly lower during an acute porphyric attack (median: 0.34 ml min‐1 kg‐1; range: 0.1‐0.71, P less than 0.05) than in patients in remission (median: 0.53 ml min‐1 kg‐1; range: 0.28‐0.87) or controls (median: 0.52 ml min‐1 kg‐1; range: 0.32‐ 0.93). There was a significant negative correlation between weight‐ adjusted antipyrine clearance and the urinary excretion of the porphyrin precursors, delta‐aminolaevulinic acid (r = 0.86, P less than 0.001) and porphobilinogen (r = 0.82, P less than 0.002). These data suggest that the more severe the porphyric attack, the greater the impairment of hepatic monooxygenase activity.